Methods and compositions for treatment of cancer using oncolytic RSV activity

A method of treating a prostate cancer in a subject, comprising administering to the subject an oncolytically effective amount of a respiratory syncytial virus (RSV), wherein the RSV does not comprise a heterologous nucleotide sequence, thereby treating the prostate cancer in the subject.

A method of reducing metastasis of a primary prostate cancer in a subject, comprising administering to the subject an oncolytically effective amount of a respiratory syncytial virus (RSV), wherein the RSV does not comprise a heterologous nucleotide sequence, thereby reducing metastasis of the primary prostate cancer in the subject.

A method of reducing tumor size and/or tumor burden in a subject comprising a prostate tumor, comprising administering to the subject an oncolytically effective amount of a respiratory syncytial virus (RSV), wherein the RSV does not comprise a heterologous nucleotide sequence, thereby reducing tumor size and/or tumor burden in the subject.

A method of inducing apoptosis of a prostate neoplastic or tumor cell in a subject, comprising administering to the subject an oncolytically effective amount of a respiratory syncytial virus (RSV), wherein the RSV does not comprise a heterologous nucleotide sequence, thereby inducing apoptosis of the prostate neoplastic or tumor cell in the subject.

A method of reducing pain caused by a prostate tumor in a subject, comprising administering to the subject an oncolytically effective amount of a respiratory syncytial virus (RSV), wherein the RSV does not comprise a heterologous nucleotide sequence, thereby reducing pain caused by the prostate tumor in the subject.

A method of increasing the sensitivity of a prostate tumor cell to radiation, comprising infecting the prostate tumor cell with a respiratory syncytial virus (RSV), wherein the RSV does not comprise a heterologous nucleotide sequence, thereby increasing the sensitivity of the prostate tumor cell to radiation.

A method of increasing the sensitivity of a prostate tumor cell to a chemotherapeutic agent, comprising infecting the prostate tumor cell with a respiratory syncytial virus (RSV), wherein the RSV does not comprise a heterologous nucleotide sequence, thereby increasing the sensitivity of the prostate tumor cell to a chemotherapeutic agent.

A method of sensitizing a prostate tumor cell to an immune response against RSV, comprising infecting the prostate tumor cell with a respiratory syncytial virus (RSV), wherein the RSV does not comprise a heterologous nucleotide sequence, whereby the respiratory syncytial virus expresses respiratory syncytial virus antigen on the surface of the prostate tumor cell, thereby sensitizing the prostate tumor cell to an immune response against respiratory syncytial virus.

A method of treating a prostate tumor or neoplasm in a subject, comprising removing the prostate tumor or neoplasm from the subject and administering to the subject an oncolytic amount of a respiratory syncytial virus (RSV), wherein the RSV does not comprise a heterologous nucleotide sequence, thereby treating a prostate tumor or neoplasm in the subject.

A method of reducing the likelihood of recurrence of a prostate tumor or neoplasm in a subject, comprising removing the prostate tumor or neoplasm from the subject and administering to the subject an oncolytic amount of a respiratory syncytial virus (RSV), wherein the RSV does not comprise a heterologous nucleotide sequence, thereby reducing the likelihood of recurrence of a prostate tumor or neoplasm in the subject.

A method of eliminating or reducing the number of neoplastic prostate cells in an ex vivo population of neoplastic prostate cells and normal prostate cells, comprising contacting the population with a respiratory syncytial virus (RSV), wherein the RSV does not comprise a heterologous nucleotide sequence, under conditions whereby the respiratory syncytial virus can infect the prostate cells and kill the neoplastic prostate cells, thereby eliminating or reducing the number of neoplastic prostate cells in the ex vivo population.